宫颈癌免疫学发病机制研究进展

doi:10.12280/gjfckx.20210785

摘要/Abstract

摘要：

宫颈癌发病率居妇科恶性肿瘤首位,人乳头瘤病毒（HPV）感染是宫颈癌发生的先决条件,其中高危型HPV持续性感染极大提高了宫颈癌发病风险。HPV感染后,其DNA整合至宿主细胞DNA中,整合过程会导致许多病毒编码的早期和晚期基因缺失,进一步导致宿主细胞周期失控,从而导致宫颈病变发生。同时,HPV通过多种途径使宫颈免疫微环境发生变化,从而导致机体局部免疫功能下降,进而导致免疫逃逸发生,促进疾病进展。这期间,不仅经历了巨噬细胞、自然杀伤细胞和树突状细胞等参与的固有免疫过程,还经历了以T细胞为主的适应性免疫应答。上述各种免疫细胞及其分泌的细胞因子相互影响、相互协同,共同在宫颈癌免疫逃逸及肿瘤免疫应答中起着重要作用。明确HPV感染、免疫细胞、免疫因子与免疫逃逸的关系,将为宫颈癌治疗提供方向。

关键词: 宫颈肿瘤, 乳头状瘤病毒科, 巨噬细胞, 杀伤细胞,天然, 树突状细胞, T淋巴细胞

Abstract:

The incidence of cervical cancer ranks first in gynecological malignancies. Human papilloma virus (HPV) infection is a prerequisite for the occurrence of cervical cancer. Among them, persistent infection of high-risk HPV greatly increases the risk of cervical cancer. After HPV infection, its DNA is integrated into the host cell DNA, and the integration process will lead to the deletion of many early and late genes encoded by the virus, which further leads to the uncontrolled host cell cycle, resulting in cervical lesions. At the same time, HPV changes the immune microenvironment of the cervix through a variety of ways, which leads to the decline of the body′s local immune function, which in turn leads to immune escape and promotes disease progression. During this period, not only experienced the innate immune process involving macrophages, natural killer cells and dendritic cells, but also experienced the adaptive immune response dominated by T cells. The above-mentioned various immune cells and their secreted cytokines interact and cooperate with each other, and together play an important role in cervical cancer immune escape and tumor immune response. Clarifying the relationship between HPV infection, immune cells, immune factors and immune escape will provide directions for cervical cancer treatment.

Key words: Uterine cervical neoplasms, Papillomaviridae, Macrophages, Killer cells,natural, Dendritic cells, T-lymphocytes

王佳森, 张妍, 付晓雪, 陈芳. 宫颈癌免疫学发病机制研究进展[J]. 国际妇产科学杂志, 2022, 49(2): 207-211.

WANG Jia-sen, ZHANG Yan, FU Xiao-xue, CHEN Fang. Research Progress of Immunological Pathogenesis of Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 207-211.

参考文献 36

[1]	Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health, 2020, 8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. doi: 10.1016/S2214-109X(19)30482-6
[2]	Joharinia N, Farhadi A, Hosseini SY, et al. Association of HPV16 and 18 genomic copies with histological grades of cervical lesions[J]. Virusdisease, 2019, 30(3):387-393. doi: 10.1007/s13337-019-00545-2. doi: 10.1007/s13337-019-00545-2 pmid: 31803806
[3]	Gupta SM, Mania-Pramanik J. Molecular mechanisms in progression of HPV-associated cervical carcinogenesis[J]. J Biomed Sci, 2019, 26(1):28. doi: 10.1186/s12929-019-0520-2. doi: 10.1186/s12929-019-0520-2
[4]	范飞, 柳欣林, 李智海, 等. 人乳头瘤病毒衣壳蛋白结构生物学研究进展[J]. 中国生化药物杂志, 2016, 5:20-23,27. doi: 10.3969/j.issn.1005-1678.2016.05.06. doi: 10.3969/j.issn.1005-1678.2016.05.06
[5]	Ren S, Gaykalova DA, Guo T, et al. HPV E2, E4, E 5 drive alternative carcinogenic pathways in HPV positive cancers[J]. Oncogene, 2020, 39(40):6327-6339. doi: 10.1038/s41388-020-01431-8. doi: 10.1038/s41388-020-01431-8
[6]	Egawa N, Wang Q, Griffin HM, et al. HPV16 and 18 genome amplification show different E4-dependence, with 16E4 enhancing E1 nuclear accumulation and replicative efficiency via its cell cycle arrest and kinase activation functions[J]. PLoS Pathog, 2017, 13(3):e1006282. doi: 10.1371/journal.ppat.1006282. doi: 10.1371/journal.ppat.1006282
[7]	Li S, Hong X, Wei Z, et al. Ubiquitination of the HPV Oncoprotein E6 Is Critical for E6/E6AP-Mediated p53 Degradation[J]. Front Microbiol, 2019, 10:2483. doi: 10.3389/fmicb.2019.02483. doi: 10.3389/fmicb.2019.02483
[8]	Nogueira MO, Hošek T, Calçada EO, et al. Monitoring HPV-16 E7 phosphorylation events[J]. Virology, 2017, 503:70-75. doi: 10.1016/j.virol.2016.12.030. doi: S0042-6822(16)30413-5 pmid: 28126639
[9]	Smelov V, Elfström KM, Johansson AL, et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial[J]. Int J Cancer, 2015, 136(5):1171-1180. doi: 10.1002/ijc.29085. doi: 10.1002/ijc.29085
[10]	Doorbar J. Model systems of human papillomavirus-associated disease[J]. J Pathol, 2016, 238(2):166-179. doi: 10.1002/path.4656. doi: 10.1002/path.4656
[11]	Raikhy G, Woodby BL, Scott ML, et al. Suppression of Stromal Interferon Signaling by Human Papillomavirus 16[J]. J Virol, 2019, 93(19):e00458-19. doi: 10.1128/JVI.00458-19. doi: 10.1128/JVI.00458-19
[12]	Uppendahl LD, Dahl CM, Miller JS, et al. Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review[J]. Front Immunol, 2018, 8:1825. doi: 10.3389/fimmu.2017.01825. doi: 10.3389/fimmu.2017.01825
[13]	Stanley MA. Epithelial cell responses to infection with human papillomavirus[J]. Clin Microbiol Rev, 2012, 25(2):215-222. doi: 10.1128/CMR.05028-11. doi: 10.1128/CMR.05028-11
[14]	刘洪博, 王文智, 石庆芳. NK细胞和Treg细胞亚群在宫颈癌患者外周血中表达及临床意义[J]. 中国老年学杂志, 2020, 40(2):284-287. doi: 10.3969/j.issn.1005-9202.2020.02.018. doi: 10.3969/j.issn.1005-9202.2020.02.018
[15]	王玲. NK细胞对宫颈癌中免疫逃逸机制的影响[D]. 天津:天津医科大学, 2019.
[16]	Miura S, Kawana K, Schust DJ, et al. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV[J]. J Virol, 2010, 84(22):11614-11623. doi: 10.1128/JVI.01053-10. doi: 10.1128/JVI.01053-10
[17]	Hacke K, Rincon-Orozco B, Buchwalter G, et al. Regulation of MCP-1 chemokine transcription by p53[J]. Mol Cancer, 2010, 9:82. doi: 10.1186/1476-4598-9-82. doi: 10.1186/1476-4598-9-82
[18]	McClellan JL, Davis JM, Steiner JL, et al. Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303(10):G1087-G1095. doi: 10.1152/ajpgi.00252.2012. doi: 10.1152/ajpgi.00252.2012
[19]	周超. 肿瘤相关巨噬细胞(TAM)及Tim-3在宫颈癌中的作用及机制研究[D]. 济南:山东大学, 2018.
[20]	Ding H, Cai J, Mao M, et al. Tumor-associated macrophages induce lymphangiogenesis in cervical cancer via interaction with tumor cells[J]. APMIS, 2014, 122(11):1059-1069. doi: 10.1111/apm.12257. doi: 10.1111/apm.12257 pmid: 24698523
[21]	Hong IS. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types[J]. Exp Mol Med, 2016, 48(7):e242. doi: 10.1038/emm.2016.64. doi: 10.1038/emm.2016.64
[22]	Lukic A, Larssen P, Fauland A, et al. GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures[J]. FASEB J, 2017, 31(10):4370-4381. doi: 10.1096/fj.201700319R. doi: 10.1096/fj.201700319R pmid: 28637652
[23]	Liu WH, Liu JJ, Wu J, et al. Retraction: Novel Mechanism of Inhibition of Dendritic Cells Maturation by Mesenchymal Stem Cells via Interleukin-10 and the JAK1/STAT3 Signaling Pathway[J]. PLoS One, 2018, 13(3):e0194455. doi: 10.1371/journal.pone.0194455. doi: 10.1371/journal.pone.0194455
[24]	Vopenkova K, Mollova K, Buresova I, et al. Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy[J]. J Cell Mol Med, 2012, 16(11):2827-2837. doi: 10.1111/j.1582-4934.2012.01614.x. doi: 10.1111/j.1582-4934.2012.01614.x pmid: 22882679
[25]	Long J, Hu Z, Xue H, et al. Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway[J]. Cancer Sci, 2019, 110(8):2357-2367. doi: 10.1111/cas.14091. doi: 10.1111/cas.14091
[26]	侯萍, 陈龙, 刘艳生. 宫颈癌患者肿瘤浸润性树突状细胞表达水平及其临床意义[J]. 广西医科大学学报, 2017, 34(12):1762-1765. doi: 10.16190/j.cnki.45-1211/r.2017.12.023. doi: 10.16190/j.cnki.45-1211/r.2017.12.023
[27]	余杨, 邹晶晶. 高危型人乳头状瘤病毒和Th细胞因子与宫颈病变的关系及意义[J]. 中国妇幼卫生杂志, 2016, 7(2):51-54. doi: 10.19757/j.cnki.issn1674-7763.2016.02.014. doi: 10.19757/j.cnki.issn1674-7763.2016.02.014
[28]	齐涵沁, 朱红芬, 张耀辉. Th1、Th2、Th17、Treg细胞在宫颈癌患者外周血中的变化及意义[J]. 中国妇幼保健, 2017, 32(3):595-597. doi: 10.7620/zgfybj.j.issn.1001-4411.2017.03.61. doi: 10.7620/zgfybj.j.issn.1001-4411.2017.03.61
[29]	周萍, 冉晓敏. 人乳头瘤病毒感染宫颈病变患者外周血辅助性T17细胞、T细胞和炎症因子的变化及临床意义[J]. 中国妇幼保健, 2019, 34(6):1242-1245. doi: 10.7620/zgfybj.j.issn.1001-4411.2019.06.11. doi: 10.7620/zgfybj.j.issn.1001-4411.2019.06.11
[30]	Lin W, Zhang HL, Niu ZY, et al. The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden[J]. BMC Womens Health, 2020, 20(1):126. doi: 10.1186/s12905-020-00972-0. doi: 10.1186/s12905-020-00972-0
[31]	玄秀云, 张月, 雷波, 等. Th22细胞通过释放IL-22活化宫颈癌细胞AKT通路促进其增殖[J]. 免疫学杂志, 2017, 33(10):856-860,866. doi: 10.13431/j.cnki.immunol.j.20170150. doi: 10.13431/j.cnki.immunol.j.20170150
[32]	田馨莉, 矫俊, 张腾, 等. Th22细胞联合Th17细胞在宫颈癌外周血中的表达及意义[J]. 山东大学学报(医学版), 2015, 53(7):43-47. doi: 10.6040/j.issn.1671-7554.0.2014.964. doi: 10.6040/j.issn.1671-7554.0.2014.964
[33]	胡云双, 周旺展, 张颖, 等. Th22和Th17细胞在宫颈癌患者外周血中的表达[J]. 温州医科大学学报, 2019, 49(3):210-213. doi: 10.3969/j.issn.2095-9400.2019.03.011. doi: 10.3969/j.issn.2095-9400.2019.03.011
[34]	王丹红, 张斌, 高海燕, 等. DC诱导CTL治疗HPV感染宫颈癌患者的疗效观察[J]. 中国肿瘤生物治疗杂志, 2014, 21(5):570-573. doi: 10.3872/j.issn.1007-385X.2014.05.016. doi: 10.3872/j.issn.1007-385X.2014.05.016
[35]	Campo MS, Graham SV, Cortese MS, et al. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells[J]. Virology, 2010, 407(1):137-142. doi: 10.1016/j.virol.2010.07.044. doi: 10.1016/j.virol.2010.07.044 pmid: 20813390
[36]	Mehta AM, Jordanova ES, Kenter GG, et al. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma[J]. Cancer Immunol Immunother, 2008, 57(2):197-206. doi: 10.1007/s00262-007-0362-8. doi: 10.1007/s00262-007-0362-8